Data Proves It: Synthgene Low-dsRNA T7 Polymerase Delivers Industry-Leading Performance!

As mRNA in vitro transcription (IVT) systems continue to evolve toward higher quality and lower impurity profiles, the performance of the core T7 RNA polymerase directly determines the ultimate potential of the final product. Synthgene recently announced a significant milestone: its low-dsRNA T7 enzyme achieved top performance in an international third-party blind test, earning recognition from leading researchers. The study was led by Andrew Varley, the founding Head and R&D Lead of the RNA & Formulation Core at the University of British Columbia. A highly influential figure in the field, Varley has long focused on mRNA process development and the optimization of delivery systems. His team is dedicated to establishing standardized benchmarking systems for mRNA technology, emphasizing the role of third-party data in enhancing industry transparency and the efficiency of technical decision-making.